TY - JOUR
T1 - Facilitation of inhibitory avoidance by hypertonic saline is reversed by a vasopressin and a nicotinic antagonist
AU - Baratti, Carlos M.
AU - Faiman, Claudia P.
AU - De Erausquin, Gabriel A.
N1 - Funding Information:
Member of the Carrera del Investigador Cientifico (CONICET) and to whom reprint requests and correspondence should be addressed. 2 The authors express their thanks to Professor Dr. M. Manning, Department of Biochemistry, Medical College of Ohio, Toledo, Ohio, for his generous gift of the vasopressin antagonist, to Mrs. Maria L. Arbeletche for her cordial help with the English version, and to Miss Julia N. Morales for the typing of the manuscript. Work supported by Grant 30902403/85 from CONICET to C.M.B.
PY - 1989/5
Y1 - 1989/5
N2 - Hypertonic saline (1 ml of 0.25, 0.50, and 1.00 M NaCl, ip) facilitated retention of a one-trial, step-through inhibitory avoidance task when injected into male Swiss mice 10 min after training, as indicated by retention performance 48 h later. A similar result was obtained after a subcutaneous injection of lysine vasopressin (LVP, 0.03 μg/kg). Neither hypertonic saline nor LVP modified latencies to step-through of mice that had not received a footshock during training. The enhancement of retention produced both by hypertonic saline and by LVP was prevented by the vasopressin receptor antagonist AAVP (0.01 μg/kg, sc) given after training, but 10 min before the treatments. The effect of hypertonic saline was also prevented by the central acting cholinergic nicotinic receptor antagonist mecamylamine (5 mg/kg, sc). On the contrary, neither hexamethonium (5 mg/kg, sc), a peripheral acting nicotinic receptor blocker, nor atropine (0.5 mg/kg, sc) or methylatropine (0.5 mg/kg, sc), two anticholinergic drugs which are known to act on cholinergic muscarinic receptors, prevented the effect of post-training hypertonic saline. These results suggest that a peripheral osmotic stimulus, probably through an endogenous release of vasopressin, may be behaviorally significant, and are consistent with the view that vasopressin may modulate the activity of central cholinergic nicotinic mechanisms which are critical for the behavioral change observed.
AB - Hypertonic saline (1 ml of 0.25, 0.50, and 1.00 M NaCl, ip) facilitated retention of a one-trial, step-through inhibitory avoidance task when injected into male Swiss mice 10 min after training, as indicated by retention performance 48 h later. A similar result was obtained after a subcutaneous injection of lysine vasopressin (LVP, 0.03 μg/kg). Neither hypertonic saline nor LVP modified latencies to step-through of mice that had not received a footshock during training. The enhancement of retention produced both by hypertonic saline and by LVP was prevented by the vasopressin receptor antagonist AAVP (0.01 μg/kg, sc) given after training, but 10 min before the treatments. The effect of hypertonic saline was also prevented by the central acting cholinergic nicotinic receptor antagonist mecamylamine (5 mg/kg, sc). On the contrary, neither hexamethonium (5 mg/kg, sc), a peripheral acting nicotinic receptor blocker, nor atropine (0.5 mg/kg, sc) or methylatropine (0.5 mg/kg, sc), two anticholinergic drugs which are known to act on cholinergic muscarinic receptors, prevented the effect of post-training hypertonic saline. These results suggest that a peripheral osmotic stimulus, probably through an endogenous release of vasopressin, may be behaviorally significant, and are consistent with the view that vasopressin may modulate the activity of central cholinergic nicotinic mechanisms which are critical for the behavioral change observed.
UR - http://www.scopus.com/inward/record.url?scp=0024588149&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024588149&partnerID=8YFLogxK
U2 - 10.1016/S0163-1047(89)91065-0
DO - 10.1016/S0163-1047(89)91065-0
M3 - Article
C2 - 2525022
AN - SCOPUS:0024588149
SN - 0163-1047
VL - 51
SP - 424
EP - 435
JO - Behavioral and Neural Biology
JF - Behavioral and Neural Biology
IS - 3
ER -